NCT07075718 - Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant | Biotech Hunter

Enrollment

610

Participants

Timeline

Start Date

June 12, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2032

Conditions

Glaucoma

Interventions

DRUG

Gen 2 Travoprost Intracameral Implant

travoprost

DRUG

Timolol eye drops 0.5%

timolol 0.5%

PROCEDURE

Sham Procedure

sham implant administration

OTHER

Placebo eye drops

artificial tears

Trial Locations (3)

RECRUITING

Glaukos Investigative Site, Oklahoma City

RECRUITING

Glaukos Clinical Site, El Paso

RECRUITING

Glaukos Investigative Site, Grand Junction